Get started
Eli Lilly and CompanyEli Lilly and CompanyEli Lilly and Company

Eli Lilly and Company

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options Bonds

LLY trade ideas

LLY bounce to $822 (+dividend)MODs have suggested that I provide more detail about the picks I make. Sorry. I'm not as verbose as y'all, and I don't like things to be complicated. My trading plan is very simple. I buy or sell at top & bottom of parallel channels. I confirm when price hits Fibonacci levels. So... Here's why I'm picking this symbol to do the thing. Price at bottom channels (period 100 52 39 & 26) Stochastic Momentum Index (SMI) at oversold level VBSM is spiked negative Price at or near 1.618 Fibonacci level In at $752.25 Target is $822 or channel top Stop loss is $746
NYSE:LLYLong
by chancethepug
4
Eli Lilly is facing problems after the earnings presentation🔴 Eli Lilly is facing problems after the earnings presentation NYSE:LLY has broken an especially important support and is now in free fall. Avoid buying it now. The break also activates the bearish double top and that means that the $550 is the target of the pattern. If you look close to the chart, the volume appears in the $550-600 area, which is very similar to the double top target price. $725 is the last support before a free fall to under $600.
NYSE:LLYShort
by TopChartPatterns
ELI LILLY: This consolidation is a buy opportunity.Eli Lilly is neutral on its 1D technical outlook (RSI = 52.880, MACD = 1.910, ADX = 25.797) as well as on 1W as for the past 7 weeks it has turned sideways. This consolidation is taking place half-way through the new bullish wave of the Channel Up that started in early 2023. As you see it is supported by the 1W MA50 and every bullish wave in the beginning was almost at +50% but the latest one was +35%. Consequently we expect a minimum of +46.22% from the bottom and that's what we're aiming for (TP = 1,095). See how our prior idea has worked out: ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:LLYLong
by InvestingScope
ELI LILLY Always a solid buy below its 1D MA50.Eli Lilly (LLY) broke on Friday below its 1D MA50 (blue trend-line) for the first time since August 09. As the stock trades within a long-term Channel Up since the March 01 2023 bottom, every time the price was below the 1D MA50, it didn't stay for long, thus providing the most effective buy entry. Even though it could dip some more as with July's decline (only such case though out of 6 corrections), as long as the 1D MA200 (orange trend-line) holds, we expect the Channel Up to be extended. The initial Higher Highs were closer to the 1.5 Fibonacci Channel extension, the last one however was exactly on the 1.0 Fib. As a result, we will take a more conservative Target on that trend-line, thus turning bullish now and aiming at $1100 by the end of the year. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
Positive Signs for Eli Lilly : Upward Movement at a Low PointThe LLY price seems to have reached a bottom and is now showing signs of upward movement. This trend could indicate a potential reversal, making it an attractive opportunity for investment. If the upward momentum continues, it may suggest increasing confidence in the stock's future performance. However, it’s essential to consider other factors such as market conditions, company fundamentals, and your own investment strategy before making a decision.
NYSE:LLYLong
by Joekenstein7
LLY: Entry Volume, Target, StopEntry: > 972.53 Volume: > 3.184M Target: 1,117.98 area (this is an area, no guarantees, you should be selling on the way up) Stop: Depending on your risk tolerance; Based on an entry of 972.53, 899.93 gets you 2/1 Reward to Risk Ratio. This LONG swing trade idea is not trade advice and is strictly based on my ideas and technical analysis. No due diligence or fundamental analysis was performed while evaluating this trade idea. Do not enter a trade based on my idea, do not follow anyone blindly, do your own analysis and due diligence. I am not a professional trader.
NYSE:LLYLong
by tradepatiently
1
LLY: The Next Support Levels to Watch!On the daily chart, after a strong rally towards the resistance level at $966.10, LLY has experienced a sharp pullback. The stock failed to break through the key resistance and showed a strong rejection at that level, indicating a potential top signal. The bearish momentum is evident as the price is heading toward a possible retracement zone. The Fibonacci retracement levels show key levels to watch, with the 38.2% retracement near $880, and further possible retracements toward 50% at $849 and 61.8% at $825. The 21-day EMA is still trending upwards but is now being tested as the price begins to weaken. If lost, then the retracements will be our next targets. On the weekly chart, a clear V-shape recovery is visible, which culminated in a significant rise back toward the $966 resistance area. However, the rejection at this level has formed a potential double top, which is often a bearish reversal signal. The price has now pulled back sharply, which aligns with the signals on the daily chart. If the price continues to decline, the $850 area around the 21-week EMA will be critical support levels to monitor, whichc coincides witth the 50% retracement level observed on the daily chart. If the price breaks below these levels, it could indicate a deeper correction is underway. In conclusion, LLY appears to be in a corrective phase after failing to break through the key resistance at $966. For now, we should keep an eye on the key Fibonacci retracement levels and the 21-EMA for potential support during this pullback. A continued failure to hold these levels could lead to more downside pressure in the short term. For more detailed technical analyses and insights like this, be sure to follow my account. Your support helps me continue providing valuable content to help you make informed trading decisions. Remember, real trading is reactive, not predictive, so let's stay focused on the key points described above and only trade when there is confirmation. “To anticipate the market is to gamble. To be patient and react only when the market gives the signal is to speculate.” — Jesse Lauriston Livermore All the best, Nathan.
NYSE:LLY
by Nathan_The_Finance_Hydra
Eli Lilly's Zepbound: A Game-Changer for Obesity Treatment?In a groundbreaking move that could redefine the landscape of obesity treatment, Eli Lilly has slashed the price of its weight loss drug, Zepbound, by half. But is this simply a strategic business decision, or is it a beacon of hope for millions struggling with obesity? Join us as we delve into the implications of this bold move and explore the potential impact on the future of weight management. Imagine a world where obesity is no longer a daunting, insurmountable challenge. A world where effective, affordable treatments are accessible to all who need them. Eli Lilly's recent announcement of a significant price reduction for Zepbound brings us closer to that reality. By making this groundbreaking decision, Eli Lilly has not only demonstrated its commitment to patient access but has also sent a powerful message to the broader healthcare industry. This move has the potential to disrupt the status quo, challenging the outdated policies and practices that have hindered progress in obesity treatment. As we explore the implications of Eli Lilly's decision, we must consider the broader context of the obesity epidemic. For decades, obesity has been stigmatized and overlooked as a serious medical condition. Many individuals struggling with weight loss have faced limited treatment options and significant financial burdens. Eli Lilly's move to lower the price of Zepbound could be a game-changer in this regard. By making the drug more affordable, the company is empowering patients to take control of their health and pursue a healthier lifestyle. This could lead to a significant increase in the number of people seeking treatment for obesity, ultimately improving public health outcomes. However, it is important to note that this is just one step in a larger journey. While Eli Lilly's decision is undoubtedly a positive development, more needs to be done to address the systemic issues that contribute to the obesity epidemic. Policymakers, healthcare providers, and communities must work together to create a supportive environment that promotes healthy eating, physical activity, and access to affordable, effective treatments. In conclusion, Eli Lilly's announcement of a price reduction for Zepbound represents a significant milestone in the fight against obesity. By making this drug more accessible, the company is not only helping individuals achieve their weight loss goals but also challenging the broader healthcare system to prioritize obesity treatment.
NYSE:LLYLong
by signalmastermind
WATCHLIST 8/25 PART 2AMEX:IWM - Russell 2000 Outshines S&P 500, Nasdaq 100 As Powell Eyes Rate Cuts. Looking to add calls as long as $220 holds for a move towards $225 and higher. BMV:BRKB - another stock breaking all time highs on Friday. Stock is breaking out on charts. Calls above $455 for a move towards $470. Stock is strong on indicators. NYSE:LLY - the company announced results showing “it Tirzepatide injections reduced the risk of progression to type 2 diabetes by 94% in adults with pre-diabetes and obesity.” looking for calls above $950 for a move towards MIL:1K and higher NASDAQ:COIN - another Bitcoin related stock on watch as bitcoin moves higher. Calls added in group for swing. Next resistance at $216.6. More upside above that level. NYSE:HD - Stock breaking recent highs at $376. Stock is a decent uptrend. Rate cut news should help. Calls above $377 for a move towards $385 and $400. Stock is strong on indicator level.
NYSE:LLYLong
by TheStockTraderHub
ELI LILLY Recovered all losses from its High! What's next?Eli Lilly and Company (LLY) posted a miraculous bullish reversal in the past 2 weeks, recovering yesterday all of the losses of the brutal correction since its July 15 All Time High. Having rebounded on its 1D MA200 (orange trend-line) while the 1D RSI touched the 30.00 oversold barrier for the first time since February 28 2023, we can claim that LLY's Channel Up now sets eyes for its next Higher High. This pattern is best illustrated with the use of the Fibonacci Channel levels. After initially holding the 1.0 Fib as Resistance, the 'ceiling' is now the 1.5 Fib extension, basically has been since September 12 2023. The interesting parameter of this pattern is that every approximately +35.00 to +40.00% rise, the price pulls back or turns sideways (red arc pattern) until it eventually hits the 1D MA50 (blue trend-line). As the stock completes a +35% rise from the bottom, a little above the 1000 mark, we expect it to turn sideways at best. The target after that is $1200, exactly on the 1.0 Fibonacci level, which is still a modest one, considering that the ceiling is now the 1.5 Fib extension, as discussed above. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
#ELI LILLY $LLY back to ATH! What's next for LLY (Long term).Eli Lilly (LLY) stock jumped more than 3% to a record high on Tuesday after clinical trial results showed tirzepatide—the active ingredient in Lilly's injectable weight-loss drug Zepbound and diabetes treatment Mounjaro—lowered patients' risk of developing type 2 diabetes by 94%. LLY is climbing back toward its record high of 966.10 reached on July 15. The three-year study of patients with prediabetes and either obesity or overweight also found that those who received tirzepatide lost 22.9% of their body weight on average, compared with 2.1% for patients treated with a placebo. Eli Lilly shares jumped to an all-time high on Tuesday, bringing their year-to-date return to more than 60%. This is very bullish news for LLY. This is easily a 1k stock and a good long term investment if you want exposure to the Glucagon-like peptide-1 meds (GLP-1). LLY is number one in that field hands down. Consensus around 100bn, current 950. Research material for you: Alzheimer's potential benefits. Novo data (NVO), 2025.
NYSE:LLYLong
by BaseLineTraders
LLY: On The Brink Of CollapseEli Lilly is the one stock I've made the most returns on this year. With it's violent up and down swings, it's exactly what you look for as an options trader. As I've been observing LLY over the last few weeks, I decided to go back in time again to the origins of this monstrous parabolic move and share it with you all. If you look at the smaller time frames, you will see that LLY has filled it's gap target to the upside, but there are so many gaps to the downside. When the market does decide to fall hard, I believe LLY will fall the hardest. Is this not the perfect stock to fit the old adage, "THE BIGGER THEY ARE, THE HARDER THEY FALL?" Once LLY breaks below 747, the next targets are well below the current price. This means BIG returns for options traders. I don't see much more upside for this stock (if any), so the downside potential will play favorably. PT1 747 PT2 609 Targets are 1 to 2 months.
NYSE:LLYShort
by FiboTrader1
1